New Key Statistics Module, Z-Score and F-Score
OTCPK:VACBF Key Ratios
| Market Cap $ M | 79.17 |
| Enterprise Value $ M | -40.90 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 0.54 |
| Price/Sales | 13.33 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 6.00 |
| EPS (TTM) $ | -0.12 |
| Beneish M-Score | 175.05 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | 0.87 |
| EV-to-EBITDA | 0.91 |
| PEG | -- |
| Shares Outstanding M | 326.55 |
| Net Margin (%) | -616.32 |
| Operating Margin % | -955.55 |
| Pre-tax Margin (%) | -776.76 |
| Quick Ratio | 9.28 |
| Current Ratio | 9.28 |
| ROA % (ttm) | -20.06 |
| ROE % (ttm) | -25.16 |
| ROIC % (ttm) | -104.43 |
| Dividend Yield % | -- |
| Altman Z-Score | 1.81 |
VACBF Number of Guru Trades
VACBF Volume of Guru Trades
Gurus Latest Trades with OTCPK:VACBF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
OTCPK:VACBF is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Nykode Therapeutics AS Insider Transactions
No Available Data
News about OTCPK:VACBF
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers